JP2023505189A - 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 - Google Patents

経口利尿薬に不応性の浮腫を処置するための方法及び組成物 Download PDF

Info

Publication number
JP2023505189A
JP2023505189A JP2022533344A JP2022533344A JP2023505189A JP 2023505189 A JP2023505189 A JP 2023505189A JP 2022533344 A JP2022533344 A JP 2022533344A JP 2022533344 A JP2022533344 A JP 2022533344A JP 2023505189 A JP2023505189 A JP 2023505189A
Authority
JP
Japan
Prior art keywords
bumetanide
pharmaceutical composition
subject
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505189A5 (https=
Inventor
ラダクリシュナン，バラシンガム
エスケ，ベン
リン，ウェイ
チェン，アンドリュー，シャン
Original Assignee
レスク ファーマシューティカルズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスク ファーマシューティカルズ エルエルシー filed Critical レスク ファーマシューティカルズ エルエルシー
Publication of JP2023505189A publication Critical patent/JP2023505189A/ja
Publication of JP2023505189A5 publication Critical patent/JP2023505189A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022533344A 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 Pending JP2023505189A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943638P 2019-12-04 2019-12-04
US62/943,638 2019-12-04
PCT/US2020/063491 WO2021113775A1 (en) 2019-12-04 2020-12-04 Methods and compositions for treating edema refractory to oral diuretics

Publications (2)

Publication Number Publication Date
JP2023505189A true JP2023505189A (ja) 2023-02-08
JP2023505189A5 JP2023505189A5 (https=) 2023-12-12

Family

ID=76209409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533344A Pending JP2023505189A (ja) 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Country Status (10)

Country Link
US (5) US11123319B2 (https=)
EP (1) EP4069222A4 (https=)
JP (1) JP2023505189A (https=)
KR (1) KR20220113436A (https=)
CN (1) CN115023223A (https=)
AU (1) AU2020397176A1 (https=)
BR (1) BR112022010879A2 (https=)
CA (1) CA3160278A1 (https=)
IL (1) IL293429A (https=)
WO (1) WO2021113775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法
CA3225946A1 (en) 2021-07-16 2023-01-19 Hubert Clemens Pellikaan Aqueous bumetanide-containing liquid
AU2022425382A1 (en) * 2021-12-30 2024-07-11 Neuropro Therapeutics, Inc. Pharmaceutical composition
CN115645363B (zh) * 2022-10-31 2025-06-10 浙江普利药业有限公司 一种布美他尼注射液及其制备方法
WO2026017600A1 (en) 2024-07-15 2026-01-22 Dripel B.V. Aqueous bumetanide-containing liquid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
EP2389371A4 (en) * 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
LT2523661T (lt) * 2010-01-15 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitoriai autizmo gydymui
DK2701684T3 (en) * 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
US20150239832A1 (en) * 2012-09-04 2015-08-27 Neuro Pro Therapeutics, Inc. Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use
WO2015191473A1 (en) * 2014-06-08 2015-12-17 Autotelic Llc Fixed dose combination for pain relief without edema
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics
JP2024520788A (ja) 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRYSTENGCOMM, vol. 14, JPN6024048348, 2012, pages 2428 - 2434, ISSN: 0005671731 *
HANNE W. NIELSEN, ET AL.: ""Solubilization and Stability of Bumetanide in Vehicles for Intranasal Administration, a Pilot Study", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 6, no. 2, JPN6025034498, 2001, pages 145 - 149, ISSN: 0005671732 *

Also Published As

Publication number Publication date
US20250268853A1 (en) 2025-08-28
WO2021113775A8 (en) 2021-07-22
CN115023223A (zh) 2022-09-06
EP4069222A4 (en) 2023-12-27
US20210169833A1 (en) 2021-06-10
WO2021113775A1 (en) 2021-06-10
US11123319B2 (en) 2021-09-21
US20220287996A1 (en) 2022-09-15
US12150923B2 (en) 2024-11-26
US12558330B2 (en) 2026-02-24
KR20220113436A (ko) 2022-08-12
IL293429A (en) 2022-07-01
CA3160278A1 (en) 2021-06-10
US12329731B2 (en) 2025-06-17
EP4069222A1 (en) 2022-10-12
AU2020397176A1 (en) 2022-06-30
US20250032436A1 (en) 2025-01-30
BR112022010879A2 (pt) 2022-10-18
US11260038B1 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US12329731B2 (en) Methods and compositions for treating edema refractory to oral diuretics
AU2020256337B2 (en) Dosing regimens for echinocandin class compounds
KR102462275B1 (ko) 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
TWI815796B (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
US20100216754A1 (en) Compositions for the treatment of inflammation of the gastrointestinal tract
JP2013515018A (ja) ビタミンｄ類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
EA028749B1 (ru) Солюбилизированный капсулированный препарат 1,1-диметилэтил [(1s)-1-{[(2s,4r)-4-(7-хлор-4-метоксиизохинолин-1-илокси)-2-({(1r,2s)-1-[(циклопропилсульфонил)карбамоил]-2-этенилциклопропил}карбамоил)пирролидин-1-ил]карбонил}-2,2-диметилпропил]карбамата
JP2022037044A (ja) ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
KR20240042402A (ko) 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법
US9421268B2 (en) Pediatric oral liquid compositions containing nepadutant
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
Prisant MEET THE EXPERTS: EFFECTIVE USE OF COMBINATION DRUG THERAPY IN THE TREATMENT OF MINORITY HYPERTENSIVE POPULATIONS: Combination Therapy: Rediscovered
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260127